PDS Biotechnology Corporation Statistics
Share Statistics
PDS Biotechnology Corporation has 37.41M shares outstanding. The number of shares has increased by 18.36% in one year.
| Shares Outstanding | 37.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 36.02M |
| Failed to Deliver (FTD) Shares | 21.41K |
| FTD / Avg. Volume | 4.93% |
Short Selling Information
The latest short interest is 4.47M, so 11.95% of the outstanding shares have been sold short.
| Short Interest | 4.47M |
| Short % of Shares Out | 11.95% |
| Short % of Float | 12.42% |
| Short Ratio (days to cover) | 10.47 |
Valuation Ratios
The PE ratio is -3.58 and the forward PE ratio is -2.1.
| PE Ratio | -3.58 |
| Forward PE | -2.1 |
| PS Ratio | 0 |
| Forward PS | 312 |
| PB Ratio | 5.89 |
| P/FCF Ratio | -4.57 |
| PEG Ratio | n/a |
Enterprise Valuation
PDS Biotechnology Corporation has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.33, with a Debt / Equity ratio of 0.91.
| Current Ratio | 4.33 |
| Quick Ratio | 4.33 |
| Debt / Equity | 0.91 |
| Total Debt / Capitalization | 47.53 |
| Cash Flow / Debt | -1.42 |
| Interest Coverage | -10.23 |
Financial Efficiency
Return on equity (ROE) is -1.64% and return on capital (ROIC) is -83.39%.
| Return on Equity (ROE) | -1.64% |
| Return on Assets (ROA) | -0.72% |
| Return on Capital (ROIC) | -83.39% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.72M |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1.41M |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by -64.12% in the last 52 weeks. The beta is 1.93, so PDS Biotechnology Corporation's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | -64.12% |
| 50-Day Moving Average | 2.81 |
| 200-Day Moving Average | 3.35 |
| Relative Strength Index (RSI) | 32.52 |
| Average Volume (20 Days) | 434.60K |
Income Statement
In the last 12 months, PDS Biotechnology Corporation had revenue of $0 and earned -$42.94M in profits. Earnings per share was $-1.39.
| Revenue | 0 |
| Gross Profit | -57.33K |
| Operating Income | -43.05M |
| Net Income | -42.94M |
| EBITDA | -40.08M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.39 |
Balance Sheet
The company has $56.56M in cash and $23.85M in debt, giving a net cash position of $32.71M.
| Cash & Cash Equivalents | 56.56M |
| Total Debt | 23.85M |
| Net Cash | 32.71M |
| Retained Earnings | -144.50M |
| Total Assets | 52.45M |
| Working Capital | 33.79M |
Cash Flow
In the last 12 months, operating cash flow was -$33.64M and capital expenditures -$4, giving a free cash flow of -$33.64M.
| Operating Cash Flow | -33.64M |
| Capital Expenditures | -4 |
| Free Cash Flow | -33.64M |
| FCF Per Share | -1.09 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PDSB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -75.96% |
| FCF Yield | -49% |
Analyst Forecast
The average price target for PDSB is $14, which is 665% higher than the current price. The consensus rating is "Buy".
| Price Target | $14 |
| Price Target Difference | 665% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 18, 2019. It was a backward split with a ratio of 1:20.
| Last Split Date | Mar 18, 2019 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -4.78 |
| Piotroski F-Score | 2 |